Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announces the availability of new Human multiplex biomarker panels for the quantification of seven biomarkers related to drug-induced vascular injury. The development of the new panels was prompted by recent findings of vascular injury during pre-clinical testing for certain drugs. Researchers in drug-induced vascular injury clinical trials need to understand and identify biomarkers that will help determine the risk involved. The new multiplex biomarker vascular panels provide a more rapid, sensitive and accurate method to detect and monitor these key biomarkers, which will help better ascertain the risk while speeding the pace and increasing the accuracy of clinical phase research efforts.

The Human Vascular Injury Panels are validated for analysis of serum, plasma, and tissue culture samples. The panels were developed using Aushon SearchLight® protein array technology - a multiplex, sandwich ELISA system based on chemiluminescent or infrared detection of analytes. It features a simple 2.5 hour protocol that is very similar to protocols for traditional plate-based ELISA kits.

The new multiplex panels include the following biomarkers:

  • E-Selectin, P-Selectin, ICAM-3, Thrombomodulin, ICAM-1, VCAM-1, and SAA.

Researchers can analyze samples from clinical trials using Aushon's CLIA-certified sample testing service or by conducting the analysis themselves by using Aushon's biomarker kits and imaging system. The panels are available in a chemiluminescent format, which requires the use of the Aushon SearchLight® Plus CCD Imaging & Analysis System to read and analyze the plate.


 Aushon BioSystems


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Cardiovascular risk in psoriasis, the association between psoriatic inflammation and atherosclerosis, and the cardiovascular-risk-reducing effects of biologics